NASDAQ
27.12.24
19:22 Uhr
2,115 US-Dollar
+0,145
+7,36 %
+7,36 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 154 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and... ► Artikel lesen | |
| 12.11. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Milestone Pharmaceuticals maintains Buy rating from TD Cowen | 3 | Investing.com | ||
| 14.10. | Wainwright maintains Buy rating on Milestone Pharma stock | 1 | Investing.com | ||
| 06.09. | Milestone Pharmaceuticals Inc.: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China | 128 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 04.09. | Milestone Pharmaceuticals welcomes new board member Joseph Papa | 1 | Investing.com | ||
| 04.09. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 04.09. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 09.08. | Milestone Pharmaceuticals GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 08.08. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 107 | GlobeNewswire (Europe) | - NDA for CARDAMYST in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 - Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 - Stuart Duty and Andrew Saik Appointed... ► Artikel lesen | |
| 08.08. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.07. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST | 248 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 13.05. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 190 | GlobeNewswire (Europe) | - NDA for etripamil in PSVT resubmitted in 1Q 2024- Cash resources as of March 31, 2024 expected to fund operations into 2026- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR... ► Artikel lesen | |
| 08.04. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting | 165 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 21.03. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update | 239 | GlobeNewswire (Europe) | - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,535 | -0,55 % | Novo Nordisk speckt ab, Gerresheimer verliert ebenfalls an Wert, Eli Lilly frohlockt und auch bei Pfizer herrscht gute Laune | Noch vor Jahresende wollte Novo Nordisk neue Studiendaten zum in Entwicklung befindlichen Abnehmmedikament CagriSema vorstellen. Dieses Versprechen konnte das Unternehmen auch einlösen. Am Freitag erhielten... ► Artikel lesen | |
| GILEAD SCIENCES | 89,99 | +0,28 % | Gilead: Hohe Gewinnchance mit höchstem Risiko? | Der Ausbruch aus dem kurzfristigen Seitwärtstrend hat bisher nicht funktioniert aber das Chartbild sieht insgesamt optimistisch aus. Die Unterstützung wurde auf Schlusskursbasis nur für kurze Zeit durchbrochen... ► Artikel lesen | |
| MERCK & CO | 95,50 | 0,00 % | Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now | ||
| VERTEX PHARMACEUTICALS | 390,65 | +0,33 % | Vertex Pharmaceuticals Incorporated: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,352 | +5,72 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 14,300 | -0,35 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B | - ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed - - In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,150 | -3,02 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 9,380 | +1,96 % | Community Rückblick: wO User zu Newron Lizenzvereinbarung mit EA Pharma: "Unheimlich guter Deal!" | © Foto: Gorodenkoff / Stock.adobe.comDie Diskussion um Newron Pharma explodierte, nachdem die italienische Biotechfirma am 13.12. die Kooperation mit "EA-Pharma" aus Japan, zum Vertrieb des Hoffnungsmittels... ► Artikel lesen | |
| ROCKET LAB USA | 26,000 | +5,69 % | Spotlight on Rocket Lab USA: Analyzing the Surge in Options Activity | ||
| OPKO HEALTH | 1,427 | 0,00 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 104,00 | -5,45 % | Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance | ||
| ALTIMMUNE | 7,427 | -0,60 % | Why Altimmune Was Such a Robustly Healthy Stock on Thursday | ||
| JAZZ PHARMACEUTICALS | 118,80 | -0,50 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare... ► Artikel lesen | |
| ROYALTY PHARMA | 24,490 | +0,91 % | Jim Cramer on Royalty Pharma plc (RPRX): 'Disappointing Stock, Man, I Can't Believe It' | ||
| TG THERAPEUTICS | 31,000 | -0,29 % | TG Therapeutics, Inc.: New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent... ► Artikel lesen |
MILESTONE PHARMACEUTICALS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,115 Euro und damit +7,36 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MILESTONE PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
